FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 vaccine to include adolescents age 12 to 15 years of age

Trial data indicate immune response of adolescents was non-inferior to older participants age 16-25 years, and side effects were consistent with those reported in those 16 years of age and older. Application has been submitted in EU for use in adolescents aged 12-15 years.

US Food and Drug Administration